Tradestie Institutional Equity Comparison Engine
ZLAB vs CNTA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CNTA Overall Edge
CNTA Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Centessa Pharmaceuticals plc American Depositary Shares (CNTA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus CNTA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against CNTA sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ZLAB N/M vs CNTA N/M Fwd P/E
Growth & Margin Winner
CNTA
Op Margin -63.0% vs 0.0% ยท YoY -6.8% vs +0.0%
Momentum & Technical Winner
CNTA
1Y +9.7% vs +225.8% ยท 52W Pos 60% vs 100%
Options & Structure Winner
CNTA
UNCLASSIFIED (58th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
ZLAB
NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap
$3.0B
1M Return
+2.76%
1Y Return
+9.66%
Forward P/E
N/M
Unified AI Score
47.4 / 100
HOLD
Tech 25.0
Fund 39.0
Flow 50.0
Mom 53.5
CNTA
NASDAQ
Centessa Pharmaceuticals plc American Depositary Shares
Pharmaceutical Preparations
$40.50
+0.8% 1D
Market Cap
$6.2B
1M Return
+1.73%
1Y Return
+225.82%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 40.0
Fund 46.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ZLAB +9.66%
CNTA +225.82%
Spread: +70.86 pp (CNTA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ZLAB TTM Op. Margin: -63.0%
CNTA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs CNTA. Trailing 12-month operating profitability (ZLAB -63.0% vs CNTA 0.0%) and valuation multiples (ZLAB N/M vs CNTA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZLAB | CNTA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $6.2B | Larger Scale | CNTA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -6.8% | +0.0% | Higher Growth | CNTA |
| Operating Margin (TTM) Profitability | -63.0% | 0.0% | Higher Margin | CNTA |
| Net Profit Margin Profitability | -44.9% | 0.0% | Higher Margin | CNTA |
| Return on Equity (ROE) Capital Efficiency | -30.0% | -57.4% | Higher ROE | ZLAB |
| 52-Week Range Position Momentum | 60% ($16โ$29) | 100% ($12โ$41) | Stronger Trend | CNTA |
| Beta / 30D Volatility Risk Regime | 1.19ฮฒ ยท 78% Vol | 1.31ฮฒ ยท 4% Vol | Lower Realized Risk | CNTA |
| Unified Institutional Score Composite Signal | 47.4 / 100 (HOLD) | 61.0 / 100 (BUY) | Higher Composite | CNTA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ZLAB vs CNTA Buy Guide
ZLAB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
58th %ile
IV Regime
Balanced (25thโ60th %ile)
CNTA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ZLAB nor CNTA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.